Eagle Pharmaceuticals ( NASDAQ: EGRX ) on Wednesday said it has received a notice from Nasdaq, advising the company that it has initiated a process to delist its securities from Nasdaq because the company had not filed its Form 10-Q for the quarter ended September 30, 2023, and its Form 10-K for the year ended December 31, 2023 by May 13, 2024. The notice further advises the company’s failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 serves as an additional and separate basis for delisting. EGRX +0.
68% after hours to $4.4. Source: Press Release More on Eagle Pharmaceuticals Financial information for Eagle Pharmaceuticals.